MiCardia CE marks enCor heart valve repair device
This article was originally published in Clinica
MiCardia’s enCor mitral valve repair system is now available in Europe after the firm CE marked it. It is intended for patients with mitral valve regurgitation, where the mitral valve in the heart does not close tightly, allowing blood to flow backwards. The device, an annulosplasty ring, can be adjusted during surgery to correct any residual mitral valve regurgitation in real time on a beating heart. Irvine, California-based MiCardia is also developing a next-generation device, enCorSQ, which clinicians can adjust during minimally invasive surgery. It is designed to treat recurrent regurgitation weeks, months or years after the initial surgery. Around 20,000 mitral valve repair procedures are performed in Europe each year, MiCardia estimates.